Abstract

Diffuse brainstem glioma has a poor prognosis, and there are few long-term survivors. We looked for clinical, conventional magnetic resonance (MR), and MR spectroscopic (MRS) findings predictive of the prognosis of patients with brainstem glioma. Our institutional review board approved this retrospective study of 23 patients with diffuse intrinsic pontine or diffuse medullary brainstem glioma treated during the period 2000-2009. To evaluate prognostic values, we performed a Kaplan-Meier survival analysis (log-rank test) that incorporated the patients' age and sex, symptom duration, the presence or absence of cranial nerve palsy, long tract sign, ataxia, and cysts, the chemotherapeutic regimen, Gd enhancement, longitudinal and cerebellar extension, basilar artery encasement, and MRS parameters. Of the 23 diffuse brainstem gliomas, 19 were located at the pons (ratio of male to female patients, 1.1:1). The mean age of the 23 patients was 15.9 years (range, 4-50 years); 16 were aged <20 years. The duration of overall survival was 19.7 months; in patients with diffuse intrinsic pontine glioma, it was 16.6 months, and in patients aged <20 years, it was 11.8 months. Clinical and conventional MR findings at presentation were not predictive of the prognosis in children with diffuse intrinsic pontine glioma. In addition, a patient age <20 years and the detection of lactate by MRS were poor prognostic factors. The MRS detection of lactate is a prognostic factor in patients with diffuse intrinsic pontine glioma. Additional studies of larger patient populations using other imaging modalities are needed.

Highlights

  • Diffuse brainstem glioma has a poor prognosis, and there are few long-term survivors

  • We found that the MR spectroscopic (MRS) detection of lactate is a poor prognostic factor in patients with diffuse intrinsic pontine glioma

  • Ours is the first documentation of the power of 1HMRS for predicting the prognosis of patients with this tumor

Read more

Summary

Introduction

Diffuse brainstem glioma has a poor prognosis, and there are few long-term survivors. We looked for clinical, conventional magnetic resonance (MR), and MR spectroscopic (MRS) findings predictive of the prognosis of patients with brainstem glioma. The MRS detection of lactate is a prognostic factor in patients with diffuse intrinsic pontine glioma. In vivo proton magnetic resonance spectroscopy (1HMRS) can substantially improve the noninvasive categorization of brain tumors It provides important information on tumor activity and tumor tissue characteristics that cannot be obtained by MRI alone. Yamasaki et al.: Detection of lactate by MRS in DIPG because these metabolites are absent in healthy brain tissue.[13,14,15] in addition to other 1HMRS parameters, in this study, we closely observed the levels of lactate and lipids. Our results showed that the lactate expression seen in pretreatment 1HMRS is an important prognostic factor in these patients

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call